背景:SIRPB1表达在各种肿瘤类型中上调,包括神经胶质瘤,并且已知有助于肿瘤进展;尽管如此,其在神经胶质瘤免疫环境中的作用尚不清楚。
方法:本研究,我们分析了来自GTEx数据库的1152个正常样本和来自TCGA数据库的670个神经胶质瘤样本,以研究SIRPB1的表达与临床病理特征之间的关系.此外,使用CRISPR/Cas9构建SIRPB1基因敲除THP-1细胞系,并在体外将其诱导为巨噬细胞和神经胶质瘤细胞的共培养,以了解SIRPB1在神经胶质瘤免疫环境中的作用。最后,我们建立了预测模型来预测SIRPB1对预后的影响。
结果:在神经胶质瘤中发现SIRPB1表达水平显著升高,这对免疫环境有不利影响,与患者生存率相关性较差。用某些抗体激活SIRPB1导致SYK磷酸化和随后的钙激活,MAPK,和NF-κB信号通路。与神经胶质瘤细胞相反,这种现象主要在骨髓来源的细胞中观察到。体外共培养表明,SIRPB1敲除的巨噬细胞显示IL1RA降低,CCL2和IL-8在SIRPB1异位表达后恢复,但用SYK抑制剂GS9973处理后再次降低。严重的,较低的总生存率与SIRPB1表达增加有关.利用SIRPB1的表达以及其他临床病理变量,我们建立了一个显示高度预测准确性的列线图.
结论:我们的研究表明,神经胶质瘤细胞可以通过SIRPB1被巨噬细胞激活,随后重新编程TME,提示SIRPB1可以作为胶质瘤的一个有希望的治疗靶点。
BACKGROUND: SIRPB1 expression is upregulated in various tumor types, including gliomas, and is known to contribute to tumor progression; nevertheless, its function in the immune milieu of gliomas is still mainly unknown.
METHODS: This study, we analyzed 1152 normal samples from the GTEx database and 670 glioma samples from the TCGA database to investigate the relationship between the expression of SIRPB1 and clinicopathological features. Moreover, SIRPB1 gene knockout THP-1 cell lines were constructed using CRISPR/Cas9 and were induced into a co-culture of macrophages and glioma cells in vitro to learn more about the role of SIRPB1 in the glioma immune milieu. Lastly, we established a prognostic model to predict the effect of SIRPB1 on prognosis.
RESULTS: Significantly higher levels of SIRPB1 expression were found in gliomas, which had an adverse effect on the immune milieu and correlated poorly with patient survival. SIRPB1 activation with certain antibodies results in SYK phosphorylation and the subsequent activation of calcium, MAPK, and NF-κB signaling pathways. This phenomenon is primarily observed in myeloid-derived cells as opposed to glioma cells. In vitro co-culture demonstrated that macrophages with SIRPB1 knockout showed decreased IL1RA, CCL2, and IL-8, which were recovered upon ectopic expression of SIRPB1 but reduced again following treatment with SYK inhibitor GS9973. Critically, a lower overall survival rate was linked to increased SIRPB1 expression. Making use of SIRPB1 expression along with additional clinicopathological variables, we established a nomogram that showed a high degree of prediction accuracy.
CONCLUSIONS: Our study demonstrates that glioma cells can be activated by macrophages via SIRPB1, subsequently reprogramming the TME, suggesting that SIRPB1 could serve as a promising therapeutic target for gliomas.